 |
||||||||
 |
|
 |
 |
 |
 |
 |
|
|
Active Portfolio - USAA B C D E F G H I J K L M N O P Q R S T U V W X Y Z HISTORY EUROPE PUBLIC |
||||
|
Aileron Therapeutics (USA) is developing a revolutionary class of drugs called Stapled Peptides that represent the first general solution, or "scaffold" for modulating intracellular protein-protein interactions that are critical control points to nearly all functions of a cell. http://www.aileronrx.com |
|||
|
Alios BioPharma (USA) is developing novel medicines that treat diseases in virology by activating pathways in the innate immune system. http://www.aliosbiopharma.com/ |
|||
|
Anaphore (USA) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases. http://www.anaphoreinc.com |
|||
|
CalciMedica (USA) is dedicated to the discovery and development of novel small molecule drugs for the treatment of autoimmune and inflammatory diseases. A significant focus of the company's drug discovery strategy is based on the specific inhibition of calcium release-activated calcium (CRAC) channels. http://www.calcimedica.com/ |
|||
|
CoNCERT Pharmaceuticals, Inc (USA) creates new drugs by using precision deuterium chemistry to modify the pharmacology of existing and new small molecule compounds to create a treatment benefit. http://www.concertpharma.com/ |
|||
|
Constellation Pharmaceuticals is the leading biopharmaceutical company dedicated to the development of novel therapeutics in the emerging area of epigenetics, a new field that describes how the selective regulation of chromatin state controls key cellular activities such as gene expression, cell fate decisions, and DNA damage repair. http://www.constellationpharma.com/ |
|||
|
CyDex (USA) develops and commercializes specialty pharmaceutical products based on drug delivery and formulation technologies. http://www.cydexinc.com/ |
|||
|
Genocea Biosciences (USA) - commercializing key breakthroughs in vaccine discovery and development. http://www.genocea.com/ |
|||
|
Locus Pharmaceuticals, Inc. (USA) applies its core fragment-based, computational drug design technology with its capabilities in medicinal chemistry, crystallography and biology to create small molecule product. The company has a portfolio of emerging candidates in development for cancer and inflammation. http://www.locuspharma.com/ |
|||
|
Novalar Pharmaceuticals, Inc.(USA) is a specialty pharmaceutical company.Lead asset NV-101, for the reversal of numbness associated with local dental anesthesia, has completed Phase III trials. An NDA was filed in 2007. http://www.novalarpharm.com/ |
|||
|
NeuroTherapeutics Pharma, Inc., or NTP, is a biopharmaceutical company focused on developing therapies for diseases associated with central nervous system (CNS) hyper-excitability. http://www.ntprx.com/ |
|||
|
Nupathe(USA) - developing innovative therapeutic products for the treatment of neurological and psychiatric disorders where the needs of patients are insufficiently met by current treatments http://www.nupathe.com/ |
|||
|
Rib-X Pharmaceuticals (USA) is developing novel classes of anti-microbials to address unmet needs in resistant community and hospital-acquired infections using structure-based drug design and its proprietary knowledge of the crystal structure of the 50S subunit of the ribosome and other important targets. http://www.rib-x.com/ |
|||
|
Scynexis, Inc. (USA) offers drug discovery and development services to biotech and pharmaceutical companies through a suite of research, development and products. http://www.scynexis.com/ |
|||
|
Synovex(USA) - developing novel antibody therapeutic for rheumatoid arthritis and other indications | |||
|
Trinity Biosystems (USA) is using its novel platform of oral and nasal delivery to develop proteins and peptide therapeutics.
http://www.trinitybiosystems.com/ |
|||
|
Zelos Therapeutics (USA) is developing new treatments for osteoporosis and other indications based on breakthrough discoveries in parathyroid hormone research. Lead candidate Ostabolin C is in Phase II trials. http://www.zelostherapeutics.com/ |
|||